BRISTOL-MYERS SQUIBB CO (BMY) Fundamental Analysis & Valuation

NYSE:BMY • US1101221083

Current stock price

58.29 USD
+0.62 (+1.08%)
Last:

This BMY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BMY Profitability Analysis

1.1 Basic Checks

  • BMY had positive earnings in the past year.
  • In the past year BMY had a positive cash flow from operations.
  • BMY had positive earnings in 4 of the past 5 years.
  • In the past 5 years BMY always reported a positive cash flow from operatings.
BMY Yearly Net Income VS EBIT VS OCF VS FCFBMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • With an excellent Return On Assets value of 7.83%, BMY belongs to the best of the industry, outperforming 88.54% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 38.19%, BMY belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
  • BMY has a better Return On Invested Capital (19.52%) than 95.83% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BMY is in line with the industry average of 13.06%.
  • The 3 year average ROIC (14.47%) for BMY is below the current ROIC(19.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROIC 19.52%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
BMY Yearly ROA, ROE, ROICBMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.64%, BMY belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BMY has grown nicely.
  • BMY has a better Operating Margin (35.82%) than 96.35% of its industry peers.
  • In the last couple of years the Operating Margin of BMY has grown nicely.
  • BMY has a Gross Margin of 72.63%. This is in the better half of the industry: BMY outperforms 79.69% of its industry peers.
  • BMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
BMY Yearly Profit, Operating, Gross MarginsBMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

5

2. BMY Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMY is creating value.
  • Compared to 1 year ago, BMY has more shares outstanding
  • Compared to 5 years ago, BMY has less shares outstanding
  • BMY has a better debt/assets ratio than last year.
BMY Yearly Shares OutstandingBMY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
BMY Yearly Total Debt VS Total AssetsBMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 2.49 indicates that BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BMY (2.49) is better than 65.63% of its industry peers.
  • BMY has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as BMY would need 3.51 years to pay back of all of its debts.
  • BMY has a better Debt to FCF ratio (3.51) than 89.06% of its industry peers.
  • BMY has a Debt/Equity ratio of 2.33. This is a high value indicating a heavy dependency on external financing.
  • BMY's Debt to Equity ratio of 2.33 is on the low side compared to the rest of the industry. BMY is outperformed by 79.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Altman-Z 2.49
ROIC/WACC2.26
WACC8.62%
BMY Yearly LT Debt VS Equity VS FCFBMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B 50B

2.3 Liquidity

  • A Current Ratio of 1.26 indicates that BMY should not have too much problems paying its short term obligations.
  • BMY has a worse Current ratio (1.26) than 77.60% of its industry peers.
  • A Quick Ratio of 1.14 indicates that BMY should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.14, BMY is doing worse than 75.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.14
BMY Yearly Current Assets VS Current LiabilitesBMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2

3. BMY Growth Analysis

3.1 Past

  • BMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
  • BMY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
  • The Revenue has decreased by -0.22% in the past year.
  • Measured over the past years, BMY shows a small growth in Revenue. The Revenue has been growing by 2.54% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%

3.2 Future

  • BMY is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.15% yearly.
  • BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.54% yearly.
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMY Yearly Revenue VS EstimatesBMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BMY Yearly EPS VS EstimatesBMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

8

4. BMY Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.48, the valuation of BMY can be described as very reasonable.
  • Based on the Price/Earnings ratio, BMY is valued cheaply inside the industry as 92.19% of the companies are valued more expensively.
  • BMY is valuated cheaply when we compare the Price/Earnings ratio to 26.21, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 9.20, the valuation of BMY can be described as reasonable.
  • BMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMY is cheaper than 89.06% of the companies in the same industry.
  • BMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.48
Fwd PE 9.2
BMY Price Earnings VS Forward Price EarningsBMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 92.71% of the companies in the same industry are more expensive than BMY, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, BMY is valued cheaply inside the industry as 92.71% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.24
EV/EBITDA 7.1
BMY Per share dataBMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • BMY has an outstanding profitability rating, which may justify a higher PE ratio.
  • BMY's earnings are expected to decrease with -4.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)3.19
PEG (5Y)N/A
EPS Next 2Y0.29%
EPS Next 3Y-4.05%

7

5. BMY Dividend Analysis

5.1 Amount

  • BMY has a Yearly Dividend Yield of 4.30%, which is a nice return.
  • BMY's Dividend Yield is rather good when compared to the industry average which is at 0.64. BMY pays more dividend than 96.35% of the companies in the same industry.
  • BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 4.3%

5.2 History

  • The dividend of BMY is nicely growing with an annual growth rate of 6.51%!
  • BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)6.51%
Div Incr Years4
Div Non Decr Years4
BMY Yearly Dividends per shareBMY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • BMY pays out 71.52% of its income as dividend. This is not a sustainable payout ratio.
  • BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
BMY Yearly Income VS Free CF VS DividendBMY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
BMY Dividend Payout.BMY Dividend Payout, showing the Payout Ratio.BMY Dividend Payout.PayoutRetained Earnings

BMY Fundamentals: All Metrics, Ratios and Statistics

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (4/8/2026, 9:54:08 AM)

58.29

+0.62 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners83.3%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change1.98%
Market Cap118.71B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target62.9 (7.91%)
Short Float %1.47%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield 4.3%
Yearly Dividend2.51
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years4
Div Non Decr Years4
Ex-Date04-02
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)1.39%
PT rev (3m)13.78%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)0.42%
EPS NY rev (1m)0%
EPS NY rev (3m)4.48%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)6.81%
Valuation
Industry RankSector Rank
PE 9.48
Fwd PE 9.2
P/S 2.46
P/FCF 9.24
P/OCF 8.39
P/B 6.43
P/tB N/A
EV/EBITDA 7.1
EPS(TTM)6.15
EY10.55%
EPS(NY)6.33
Fwd EY10.86%
FCF(TTM)6.31
FCFY10.82%
OCF(TTM)6.95
OCFY11.93%
SpS23.67
BVpS9.07
TBVpS-10.99
PEG (NY)3.19
PEG (5Y)N/A
Graham Number35.43
Profitability
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROCE 25.91%
ROIC 19.52%
ROICexc 23.22%
ROICexgc 84.94%
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
FCFM 26.65%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Debt/EBITDA 2.03
Cap/Depr 32.69%
Cap/Sales 2.72%
Interest Coverage 8.22
Cash Conversion 66.54%
Profit Quality 182.1%
Current Ratio 1.26
Quick Ratio 1.14
Altman-Z 2.49
F-Score7
WACC8.62%
ROIC/WACC2.26
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.98%
EPS Next 2Y0.29%
EPS Next 3Y-4.05%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.75%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%

BRISTOL-MYERS SQUIBB CO / BMY Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BMY.


What is the valuation status for BMY stock?

ChartMill assigns a valuation rating of 8 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.


How profitable is BRISTOL-MYERS SQUIBB CO (BMY) stock?

BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 8 / 10.


What is the valuation of BRISTOL-MYERS SQUIBB CO based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BRISTOL-MYERS SQUIBB CO (BMY) is 9.48 and the Price/Book (PB) ratio is 6.43.


What is the earnings growth outlook for BRISTOL-MYERS SQUIBB CO?

The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to grow by 2.98% in the next year.